Aquestive (AQST) Q1 2026 earnings review
Revenues Surge as Aquestive Buys Time for Anaphylm
Aquestive delivered a remarkably clean quarter while navigating the delay of its flagship Anaphylm product. Revenue skyrocketed 66% year-over-year to $14.4 million, driven by a massive jump in royalty payments. Crucially, the company slashed its net loss by 65% to $8.1 million. With a new $150 million debt facility securing its runway, Aquestive is preparing to increase its planned sales force by 50% and target a Q3 2026 NDA resubmission. The fundamental story remains stable: execute the FDA requests and prepare the balance sheet for a transformational launch.
🐂 Bull Case
The FDA Type A meeting is complete, aligning on human factors and PK study designs without any new CMC or clinical comparability hurdles. The Q3 2026 resubmission target is locked in.
License and royalty revenues exploded from $0.8M to $5.4M. This high-margin cash flow acts as a powerful bridge while Anaphylm waits for approval.
🐻 Bear Case
Management increased the planned sales force from 50 to 75 reps. If FDA review stretches into 2027, this bloated cost structure will torch the newly acquired cash runway.
Two clinical studies must be completed flawlessly and rapidly to meet the Q3 2026 resubmission timeline. Any misstep pushes revenue generation out indefinitely.
⚖️ Verdict: 🟢
Bullish. Management is executing exactly what they promised after the CRL setback: securing cheap debt, shrinking the baseline cash burn, and advancing the FDA dialogue. The core asset remains highly valuable.
Key Themes
Accelerating License and Royalty Revenue
High-margin revenue is accelerating rapidly. License and royalty revenue surged to $5.4 million from $0.8 million a year ago, primarily driven by Zevra. This transforms the income statement, dramatically lowering the cash burn right when the company needs to fund new Anaphylm clinical trials.
Base Manufacturing Volume Recovery
The legacy CDMO business is stable to accelerating. Manufacture and supply revenue rose 22% YoY to $8.8 million, driven by an increase in total doses shipped (33 million vs 27 million in Q1 2025). Strength in Suboxone and other partnerships ensures the lights stay on without eating into launch capital.
AdrenaVerse Innovation: AQST-108 Biomarker Discovery
Aquestive is pushing the AdrenaVerse platform forward. The Phase 1 trial for the AQST-108 topical gel found no systemic absorption issues and successfully identified a biomarker signal suppressing the TSLP cytokine (involving JAK1/JAK2 pathways). This specific innovation opens the door to massive dermatological markets like atopic dermatitis.
Sales Force Expansion Contradicts Cash Narrative
Management highlights their new $150M Oaktree debt and 'well-capitalized' status for launch. However, in the same breath, they announced a 50% increase in the planned Anaphylm field force (from 50 to 75 sales reps). Pushing fixed commercial costs higher while the drug's approval is delayed until at least late 2026/early 2027 creates a significant contradiction that threatens the cash runway if revenues don't materialize instantly upon launch.
Regulatory Execution Risk Remains High
The path forward requires new human factors validation and a new PK study. While the Type A FDA meeting provided clarity, any patient dropouts, logistical delays, or slightly off-target PK data will shatter the Q3 2026 resubmission timeline. The risk profile is stable, but absolute execution is required.
Suboxone Sunset Always Looming
While Q1 saw a bump in Suboxone revenues, the long-term trend for this legacy asset is a gradual, terminal decline. Aquestive must continue outrunning this attrition with newer products like Ondif, Sympazan, and Emylif.
Immunity to Macro Tariff Shocks
In a volatile geopolitical environment, Aquestive confirmed its U.S.-domiciled intellectual property and U.S.-based manufacturing leave its supply chain completely unaffected by proposed and implemented government tariffs. This provides exceptional margin visibility compared to peers heavily reliant on Asian or European API sourcing.
Other KPIs
Decelerating aggressively. SG&A dropped 42% from $19.1 million in 25Q1. This was largely due to the non-repeat of a $4.3M Anaphylm PDUFA fee, alongside $3.4M in lower legal fees and $2.0M less in commercial spending. The company is successfully clamping down on costs during the regulatory delay.
Stable position. Down slightly from $121.1 million at year-end 2025, but robust enough to weather the Anaphylm delay. The new $150M Oaktree debt facility saves $45M in near-term principal payments, pushing maturities out to 2031 and unlocking optionality.
Guidance
Stable. Guidance implies an accelerating run rate to hit the $48M midpoint. Q1 delivered $14.4M, meaning the company is currently pacing ahead of its own full-year implied quarterly average ($12M). Achievement is highly likely.
Stable. The maintained guidance midpoint of -$32.5M indicates management expects spending to ramp back up in the second half of the year to support the new Anaphylm clinical trials and expanded sales force preparations.
Key Questions
Sales Force ROI
What specific market data drove the decision to increase the Anaphylm launch field force by 50% from 50 to 75 reps, and how does this alter your break-even timeline post-approval?
AQST-108 Strategic Pivot
The AQST-108 update mentioned utilizing an atopic dermatitis study design. Does this represent a permanent shift away from alopecia areata as the lead indication, or are you pursuing both in parallel?
Accelerated Review Confidence
You plan to request an accelerated FDA review upon Anaphylm's resubmission in Q3. Given the historical strictness of this division, what specific precedents give you confidence this request might be granted?